Психические расстройства в общей медицине. №2 2018

К проблеме нежелательных явлений, осложняющих проведение химиотерапии (обзор зарубежной литературы)

Е.А.Макеева1, С.В.Иванов1,2, А.А.Трякин3

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 1; 2ФГБНУ «Научный центр психического здоровья». 115522, Россия, Москва, Каширское ш., д. 34; 3ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н.Блохина» Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23 makkeycarpediem@mail.ru

Стр. 23-26

1874 просмотров

Опубликовано: 25 октября 2018

Аннотация / Abstract

Обзор посвящен актуальной медико-социальной проблеме – характеристике побочных эффектов химиотерапии, значимых с точки зрения психиатрии. Информация о спектре такого рода нежелательных явлений необходима как для онкологов, интернистов, так и для психиатров в контексте выбора сбалансированной, клинически обоснованной терапии. Ключевые слова: онкология, психиатрия, химиотерапия, побочные эффекты, нейротоксичность. Для цитирования: Макеева Е.А., Иванов С.В., Трякин А.А. К проблеме нежелательных явлений, осложняющих проведение химиотерапии (обзор зарубежной литературы). Психические расстройства в общей медицине. 2018; 2: 23–26. Concomitant adverse events complicating the chemotherapy treatment: the review E.A.Makeeva1, S.V.Ivanov1,2, A.A.Tryakin3 1I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2; 2Mental Health Research Center. 115522, Russian Federation, Moscow, Kashirskoe sh., d. 34; 3N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23makkeycarpediem@mail.ru The presented review is devoted to the current medical and social problem – characteristic of the side effects of chemotherapy, which is significant issue in the context of psychiatry. Information about the spectrum of adverse events is necessary for oncologists, internists and psychiatrists to give them opportunity for use balanced, clinically-based management. Key words: oncology, psychiatry, chemotherapy, side effects, neurotoxicity. For citation: Makeeva E.A., Ivanov S.V., Tryakin A.A. Concomitant adverse events complicating the chemotherapy treatment: the review. Mental Disorders in General Medicine. 2018; 2: 23–26. Химиотерапия (ХТ) онкозаболеваний ассоциирована с большим числом нежелательных явлений, среди которых – нейротоксические эффекты...

Материал для специалистов

Полный текст статьи доступен только зарегистрированным пользователям.

Вход / Регистрация

1. Airley R. Cancer chemotherapy: Basic Science to the Clinic. Chichester, UK: Wiley-Blackwell, 2009.
2. Dropcho EJ. Neurotoxicity of cancer chemotherapy. Semin Neurol 2004; 24 (4): 419–26.
3. Dietrich J, Norden AD, Wen PY. Emerging antiangiogenic treatments for gliomas – efficacy and safety issues. Curr Opin Neurol 2008; 21 (6): 736–44.
4. Семенова А.И. Кардио- и нейротоксичность противоопухолевых препаратов (патогенез, клиника, профилактика, лечение). Практическая онкология. 2009; 10 (3). / Semenova A.I. Kardio- i neirotoksichnost' protivoopukholevykh preparatov (patogenez, klinika, profilaktika, lechenie). Prakticheskaia onkologiia. 2009; 10 (3). [in Russian]
5. Silberfarb PM, Philibert D, Levine PM. Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. Am J Psychiatry 1980; 137 (5): 597–601.
6. Van Dam FS, Schagen SB, Muller MJ et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90 (3): 210–8.
7. Bender CM, Merriman JD. Cancer- and Treatment-Related Cognitive Changes: What Can We Do Now? What Lies Ahead? Oncology (Williston Park) 2014; 28 (9): 201379.
8. Blesch KS, Paice JA, Wickham R et al. Correlates of fatigue in people with breast or lung cancer. Oncol Nurs Forum 1991; 18 (1): 81–7.
9. Pascal JP, Morrow GR, Roscoe JA et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy. Cancer 2010; 116 (14): 3513–20.
10. Priestman TJ. Cancer chemotherapy in clinical practice. Springer, 2008.
11. Sprauten M, Haugnes HS, Brydøy M et al. Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors. Ann Oncol 2015; 26 (10): 2133–40.
12. Berger AM, Hertzog M, Geary CR et al. Circadian rhythms, symptoms, physical functioning, and body mass index in breast cancer survivors. J Cancer Surviv 2012; 6 (3): 305–14.
13. Savard J, Liu L, Natarajan L et al. Breast cancer patients have progressively impaired sleep-wake activity rhythms during chemotherapy. Sleep 2009; 32 (9): 1155–60.
14. Liu L, Rissling M, Neikrug A et al. Fatigue and Circadian Activity Rhythms in Breast Cancer Patients Before and After Chemotherapy: A Controlled Study. Fatigue 2013; 1 (1–2): 12–26.
15. Roscoe JA, Morrow GR, Hickok JT et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer 2002; 10 (4): 329–36.
16. Altmaier EM, Ross WE, Moore K. A pilot investigation of the psychologic functioning of patients with anticipatory vomiting. Cancer 1982; 49 (1): 201–4.
17. Coons HL, Leventhal H, Nerenz DR et al. Anticipatory nausea and emotional distress in patients receiving cisplatin-based chemotherapy. Oncol Nurs Forum 1987; 14 (3): 31–5.
18. Lyles JN, Burish TG, Krozely MG, Oldham RK. Efficacy of relaxation training and guided imagery in reducing the aversiveness of cancer chemotherapy. J Consult Clin Psychol 1982; 50 (4): 509–24.
19. Morrow GR. Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 1982; 68 (4): 585–8.
20. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;
17 (9): 1441–9.
21. Hesketh PJ, Grunberg SM, Herrstedt J et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 2006; 14 (4): 354–60.
22. Chelkeba L, Gidey K, Mamo A et al. Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Pharm Pract (Granada) 2017; 15 (1): 877.
23. Nesse RM, Carli T, Curtis GC, Kleinman PD. Pretreatment nausea in cancer chemotherapy: a conditioned response? Psychosom Med 1980; 42 (1): 33–6.
24. Nerenz DR, Leventhal H, Love RR. Factors contributing to emotional distress during cancer chemotherapy. Cancer 1982; 50 (5): 1020–7.
25. Redd WH, Andresen GV, Minagawa RY. Hypnotic control of anticipatory emesis in patients receiving cancer chemotherapy. J Consult Clin Psychol 1982; 50 (1): 14–9.
26. Redd WH, Andrykowski MA. Behavioral intervention in cancer treatment: controlling aversion reactions to chemotherapy. J Consult Clin Psychol 1982; 50 (6): 1018–29.
27. Mercadante S, Masedu F, Balzani I et al. Prevalence of delirium in advanced cancer patients in home care and hospice and outcomes after 1 week of palliative care. Support Care Cancer 2018;
26 (3): 913–9.
28. Weinrich S, Sarna L. Delirium in the older person with cancer. Cancer 1994; 74 (Suppl. 7): 2079–91.
29. Stiefel F, Holland J. Delirium in cancer patients. Int Psychogeriatr 1991; 3 (2): 333–6.
30. Caraceni A. Drug-associated delirium in cancer patients. EJC (Suppl.) 2013; 11 (2): 233–40.
31. Küpfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 1996; 50 (4): 249–52.
32. Schellekens AF, Mulder SF, van Eijndhoven PF et al. Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases. Gen Hosp Psychiatry 2011; 33 (1): 83. e1–3.
33. Hernández R, Juan O, Alberola V. Ifosfamide-induced psychosis. Acta Oncol 2004; 43 (1): 119–20.
34. Fora A, Alabsi E, Fakih M. A case of 5-fluorouracil-induced acute psychosis. Clin Colorectal Cancer 2009; 8 (3): 166–8.
35. Celano CM, Freudenreich O, Fernandez-Robles C et al. Depressogenic effects of medications: a review. Dialogues Clin Neurosci 2011; 13 (1): 109–25.
36. Cohen MH, Johnson JR, Wang YC et al. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 2005; 10 (6): 363–8.
37. Haskell CM, Canellos GP, Leventhal BG et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease.
N Engl J Med 1969; 281 (19): 1028–34.
38. Oettgen HF, Stephenson PA, Schwartz MK et al. Toxicity of E.coli
L-asparaginase in man. Cancer 1970; 25 (2): 253–78.
39. Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa.
N Engl J Med 2001; 344 (13): 961–6.
40. Kirkwood JM, Bender C, Agarwala S et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20 (17): 3703–18.
41. Hauschild A, Gogas H, Tarhini A et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008; 112 (5): 982–94.
42. Greenberg DB, Jonasch E, Gadd MA et al. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 2000; 89 (2): 356–62.
43. Islam M, Frye RF, Richards TJ et al. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res 2002; 8 (8): 2480–7.

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

К проблеме нежелательных явлений, осложняющих проведение химиотерапии (обзор зарубежной литературы)

Материал для специалистов

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

К проблеме нежелательных явлений, осложняющих проведение химиотерапии (обзор зарубежной литературы)

Материал для специалистов

Con-Med Passport